CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to LLY

Phase 3

Development Phase

5

Upcoming Catalysts

0

Historical Events

1

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Nov '27
LLYPhase 2

Abemaciclib Phase 2 Est. Readout

Abemaciclib
Nov 2027~
CT.gov
00%
Jul '27
LLYPhase 2

Abemaciclib Phase 2 Est. Readout

Abemaciclib
Jul 2027~
CT.gov
00%
Q2 '27
LLYPhase 2

Abemaciclib Phase 2 Est. Readout (UPLIFT)

Abemaciclib
Q2 2027~Q
CT.gov
00%
Apr '27
LLYPhase 2

Abemaciclib Phase 2 Est. Readout

Abemaciclib
Apr 2027~
CT.gov
00%
Dec '26
LLYPhase 2

Abemaciclib Phase 2 Est. Readout

Abemaciclib
Dec 2026~
CT.gov
00%
Drug Information

Target Indication

Breast Cancer

Clinical Trial

NCT02308020

Last updated: 12/29/2025

Patent & Exclusivity
ActiveRLD

Latest Patent Expiry

Jul 11, 2039(12y 8m)

Patents Listed

2

Application

NDA 208716
Regulatory Approvals
EMA9/26/2018

Verzenios

Early Breast Cancer Verzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1). In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist. Advanced or Metastatic Breast Cancer Verzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.

View on EMA
Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.